Navidea Biopharmaceuticals (NYSE:NAVB) Coverage Initiated by

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB opened at $0.04 on Monday. The company has a 50-day simple moving average of $0.04 and a 200-day simple […]

Related Keywords

, Therapeutic Development Programs , Navidea Biopharmaceuticals Inc , Navidea Biopharmaceuticals Company Profile , Navidea Biopharmaceuticals , Free Report , Get Free Report , Diagnostic Substances , Therapeutic Development , Navidea Biopharmaceuticals Daily , Nyse Navb , Navb , Medical , Initiated Coverage , Stocknews Com ,